Post hoc analysis of EMBARK (1068 patients with high-risk biochemically recurrent prostate cancer): metastasis-free survival improved with enzalutamide with or without leuprolide vs leuprolide alone in under-70s and over-70s; serious adverse events were more common at ≥70.
Secondary analysisn = 1,068
Shore et al. Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age